SHMT1 as a Prognostic Indicator in Laryngeal Squamous Cell Carcinoma

Overview

This study identifies SHMT1 within amino acid metabolism-related genes as a standalone prognostic marker for laryngeal squamous cell carcinoma (LSCC). Using transcriptomic data from TCGA and GEO, a prognostic risk model was developed and validated, highlighting the clinical relevance of amino acid metabolism in LSCC prognosis.

Background

Laryngeal squamous cell carcinoma (LSCC) is a common head and neck cancer subtype with a high mortality rate and frequent late-stage diagnosis. Despite multiple treatment options, the 5-year survival rate has declined, underscoring the need for novel prognostic markers and therapeutic targets. Tumor metabolic reprogramming, especially amino acid metabolism (AAM), supports tumor growth and immune evasion, making it a promising area for intervention. This study explores the prognostic significance of AAM-related genes in LSCC using large genomic datasets.

Data Highlights

Key Findings

• Differential expression analysis identified significant amino acid metabolism-related genes (AAMRGs) between normal and LSCC tissues.
• SHMT1 emerged as a key hub gene within the AAMRG network associated with LSCC prognosis.
• A prognostic risk model incorporating SHMT1 and other AAMRGs stratified patients into high- and low-risk groups with significant survival differences.
• Model validation in independent GEO datasets confirmed its predictive accuracy for 1-, 3-, and 5-year overall survival.
• Risk score based on SHMT1 expression was an independent prognostic factor outperforming traditional clinical features.

Clinical Implications

SHMT1 expression can serve as a standalone prognostic biomarker to identify LSCC patients at higher risk of poor outcomes. Integrating SHMT1 into clinical risk models may improve patient stratification and guide personalized treatment decisions. Targeting amino acid metabolism pathways, including SHMT1, offers a potential therapeutic avenue to enhance LSCC management.

Conclusion

This study establishes SHMT1 as a novel prognostic indicator in LSCC, linking amino acid metabolism alterations to patient survival. The findings support further exploration of metabolic targets to improve prognostication and therapy in LSCC.

References

1. Global Cancer Statistics 2020 -- Head and Neck Cancer Mortality
2. Projected Mortality Rates 2025 -- Head and Neck Cancer
3. Epidemiology of Laryngeal Squamous Cell Carcinoma
4. Survival Trends in LSCC Over Decades
5. Metabolic Reprogramming in Tumors
6. Amino Acid Metabolism in Tumor Progression
7. Asparaginase Therapy in Leukemia
8. IDO1 and TDO2 Inhibitors in Cancer Immunotherapy
9. Glutaminolysis in Head and Neck Squamous Cell Carcinoma
10. Aryl Hydrocarbon Receptor and Immune Suppression in HNSCC
11. Impact of Amino Acid Metabolism on Tumor Immune Microenvironment
12. Network Analysis Tools for Functional Coupling in Genomics